WallStreetZenWallStreetZen

NASDAQ: VERV
Verve Therapeutics Inc Stock

$6.91+0.27 (+4.07%)
Updated Apr 22, 2024
VERV Price
$6.91
Fair Value Price
$1.29
Market Cap
$577.81M
52 Week Low
$6.42
52 Week High
$21.42
P/E
-2.21x
P/B
0.96x
P/S
76.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.76M
Earnings
-$200.07M
Gross Margin
100%
Operating Margin
-1,699.21%
Profit Margin
-1,701.5%
Debt to Equity
0.26
Operating Cash Flow
-$150M
Beta
2.1
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VERV Overview

Verve Therapeutics Incorporated developing a novel approach to the care of cardiovascular disease - transforming treatment from chronic management to single-course gene editing medicines. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. Verve Therapeutics was incorporated in 2018 and is headquartered in Cambridge, MA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VERV ($6.91) is overvalued by 435.34% relative to our estimate of its Fair Value price of $1.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VERV ($6.91) is not significantly undervalued (435.34%) relative to our estimate of its Fair Value price of $1.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VERV due diligence checks available for Premium users.

Be the first to know about important VERV news, forecast changes, insider trades & much more!

VERV News

Valuation

VERV fair value

Fair Value of VERV stock based on Discounted Cash Flow (DCF)
Price
$6.91
Fair Value
$1.29
Overvalued by
435.34%
VERV ($6.91) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VERV ($6.91) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VERV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.21x
Industry
16.21x
Market
41x

VERV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
5.82x
VERV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VERV's financial health

Profit margin

Revenue
$5.1M
Net Income
-$48.4M
Profit Margin
-940%
VERV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VERV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$752.7M
Liabilities
$153.2M
Debt to equity
0.26
VERV's short-term assets ($637.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERV's short-term assets ($637.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$40.7M
Investing
-$8.9M
Financing
$177.4M
VERV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VERV vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VERV$577.81M+4.07%-2.21x0.96x
ALLO$574.91M-2.02%-1.63x1.12x
PRME$573.31M+5.99%-2.19x4.31x
NVAX$569.61M+2.52%-0.75x-0.79x
NUVB$587.04M+3.08%-7.66x0.97x

Verve Therapeutics Stock FAQ

What is Verve Therapeutics's quote symbol?

(NASDAQ: VERV) Verve Therapeutics trades on the NASDAQ under the ticker symbol VERV. Verve Therapeutics stock quotes can also be displayed as NASDAQ: VERV.

If you're new to stock investing, here's how to buy Verve Therapeutics stock.

What is the 52 week high and low for Verve Therapeutics (NASDAQ: VERV)?

(NASDAQ: VERV) Verve Therapeutics's 52-week high was $21.42, and its 52-week low was $6.42. It is currently -67.74% from its 52-week high and 7.63% from its 52-week low.

How much is Verve Therapeutics stock worth today?

(NASDAQ: VERV) Verve Therapeutics currently has 83,619,279 outstanding shares. With Verve Therapeutics stock trading at $6.91 per share, the total value of Verve Therapeutics stock (market capitalization) is $577.81M.

Verve Therapeutics stock was originally listed at a price of $31.92 in Jun 17, 2021. If you had invested in Verve Therapeutics stock at $31.92, your return over the last 2 years would have been -78.35%, for an annualized return of -53.47% (not including any dividends or dividend reinvestments).

How much is Verve Therapeutics's stock price per share?

(NASDAQ: VERV) Verve Therapeutics stock price per share is $6.91 today (as of Apr 22, 2024).

What is Verve Therapeutics's Market Cap?

(NASDAQ: VERV) Verve Therapeutics's market cap is $577.81M, as of Apr 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Verve Therapeutics's market cap is calculated by multiplying VERV's current stock price of $6.91 by VERV's total outstanding shares of 83,619,279.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.